Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | NASDAQ | USD | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZNCF | OTC Markets | USD | Delayed | |
3LAZ | London | GBP | Real-time | |
AZN | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNN | Mexico | MXN | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Xetra | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed | |
AZNA | Vienna | EUR | Real-time |
For the nine months ended 30 September 2016, AstraZeneca plc (ADR) revenues decreased 5% to $17.42B. Net income decreased 18% to $1.66B. Revenues reflect United States segment decrease of 17% to $5.75B, Western Europe segment decrease of 4% to $3.73B. Net income also reflects Other Operating Income/Expenses decrease of 51% to $575M (income), Legal Provisions/Litigation Expenses increase from $24M (income) to $339M (expense).
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 6057 | 6683 | 6542 | 6454 |
Gross Profit | 4831 | 5051 | 5184 | 5173 |
Operating Income | 933 | -349 | 541 | 1109 |
Net Income | 550 | -321 | 254 | 796 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 53701 | 58595 | 56164 | 58539 |
Total Liabilities | 36765 | 38968 | 35719 | 36510 |
Total Equity | 16936 | 19627 | 20445 | 22029 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -72 | 7058 | 5216 | 3266 |
Cash From Investing Activities | -556 | -7032 | -5516 | -4955 |
Cash From Financing Activities | -2569 | -2705 | -3856 | -2570 |
Net Change in Cash | -3216 | -2831 | -4186 | -4256 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review